RESUMO
Abstract Background: Pulmonary hypertension is associated with poor prognosis in heart failure. However, non-invasive diagnosis is still challenging in clinical practice. Objective: We sought to assess the prognostic utility of non-invasive estimation of pulmonary vascular resistances (PVR) by cardiovascular magnetic resonance to predict adverse cardiovascular outcomes in heart failure with reduced ejection fraction (HFrEF). Methods: Prospective registry of patients with left ventricular ejection fraction (LVEF) < 40% and recently admitted for decompensated heart failure during three years. PVRwere calculated based on right ventricular ejection fraction and average velocity of the pulmonary artery estimated during cardiac magnetic resonance. Readmission for heart failure and all-cause mortality were considered as adverse events at follow-up. Results: 105 patients (average LVEF 26.0 ±7.7%, ischemic etiology 43%) were included. Patients with adverse events at long-term follow-up had higher values of PVR (6.93 ± 1.9 vs. 4.6 ± 1.7estimated Wood Units (eWu), p < 0.001). In multivariate Cox regression analysis, PVR ≥ 5 eWu(cutoff value according to ROC curve) was independently associated with increased risk of adverse events at 9 months follow-up (HR2.98; 95% CI 1.12-7.88; p < 0.03). Conclusions: In patients with HFrEF, the presence of PVR ≥ 5.0 Wu is associated with significantly worse clinical outcome at follow-up. Non-invasive estimation of PVR by cardiac magnetic resonance might be useful for risk stratification in HFrEF, irrespective of etiology, presence of late gadolinium enhancement or LVEF.
Resumo Fundamento: A hipertensão pulmonar está associada a mau prognóstico em insuficiência cardíaca. No entanto, o diagnóstico não-invasivo é desafiador na prática clínica. Objetivo: Avaliar a utilidade prognóstica da estimativa não-invasiva das resistências vasculares pulmonares (RVP) medidas através de ressonância magnética cardiovascular na previsão de desfechos cardiovasculares adversos em insuficiência cardíaca com fração de ejeção reduzida (ICFEr). Métodos: Registro prospectivo de pacientes com fração de ejeção do ventrículo esquerdo (FEVE) < 40% internados recentemente por insuficiência cardíaca descompensada, durante três anos. As RVP foram calculadas com base na fração de ejeção do ventrículo esquerdo e velocidade média do fluxo na artéria pulmonar estimada por ressonância magnética cardíaca. Durante a evolução, reinternação por insuficiência cardíaca e mortalidade por todas as causas foram consideradas eventos adversos. Resultados: Foram incluídos 105 pacientes (FEVE média de 26,0 ± 7,7%, etiologia isquêmica em 43%). Os valores de RVP nos pacientes que apresentaram eventos adversos durante o seguimento em longo prazo foram mais altos (6,93 ± 1,9 versus 4,6 ± 1,7 unidades Wood estimadas (uWe), p < 0,001). Na análise de regressão multivariada de Cox, RVP ≥ 5 eWu (valor de corte segundo a curva ROC) mostrou-se independentemente associada a um maior risco de eventos adversos aos 9 meses de seguimento (RR = 2,98; IC 95% = 1,12-7,88; p < 0,03). Conclusões: Em pacientes com ICFEr, a presença de RVP ≥ 5,0 uW está associada a uma evolução clínica significativamente pior. A estimativa não-invasiva da RVP através de ressonância magnética cardíaca pode ser útil na estratificação de risco em ICFEr, independentemente da etiologia, presença de realce tardio pelo gadolínio ou FEVE.
Assuntos
Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Insuficiência Cardíaca Sistólica/diagnóstico , Imagem Cinética por Ressonância Magnética/normas , Resistência Vascular/fisiologia , Insuficiência Cardíaca Sistólica/mortalidade , Insuficiência Cardíaca Sistólica/fisiopatologia , Valor Preditivo dos Testes , Prognóstico , Estudos Prospectivos , Análise de Sobrevida , Volume Sistólico/fisiologiaRESUMO
BACKGROUND: Pulmonary hypertension is associated with poor prognosis in heart failure. However, non-invasive diagnosis is still challenging in clinical practice. OBJECTIVE: We sought to assess the prognostic utility of non-invasive estimation of pulmonary vascular resistances (PVR) by cardiovascular magnetic resonance to predict adverse cardiovascular outcomes in heart failure with reduced ejection fraction (HFrEF). METHODS: Prospective registry of patients with left ventricular ejection fraction (LVEF) < 40% and recently admitted for decompensated heart failure during three years. PVR were calculated based on right ventricular ejection fraction and average velocity of the pulmonary artery estimated during cardiac magnetic resonance. Readmission for heart failure and all-cause mortality were considered as adverse events at follow-up. RESULTS: 105 patients (average LVEF 26.0 ± 7.7%, ischemic etiology 43%) were included. Patients with adverse events at long-term follow-up had higher values of PVR (6.93 ± 1.9 vs. 4.6 ± 1.7 estimated Wood Units (eWu), p < 0.001). In multivariate Cox regression analysis, PVR ≥ 5 eWu(cutoff value according to ROC curve) was independently associated with increased risk of adverse events at 9 months follow-up (HR2.98; 95% CI 1.12-7.88; p < 0.03). CONCLUSIONS: In patients with HFrEF, the presence of PVR ≥ 5.0 Wu is associated with significantly worse clinical outcome at follow-up. Non-invasive estimation of PVR by cardiac magnetic resonance might be useful for risk stratification in HFrEF, irrespective of etiology, presence of late gadolinium enhancement or LVEF.